Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 48 of 65 · 3101 articles
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from The American Journal of...
Sleep disturbance is common in IBD and may relate to disease risk and flares. Understanding which sleep problems are linked to onset or activity could point to new ways to support people with IBD.
Low-FODMAP diets are commonly used to reduce GI symptoms in IBS and sometimes in UC.
The study identifies a probiotic species (B. pseudolongum) and its acetate production as potential ways to limit a genotoxic E. coli and reduce inflammation in a mouse model — suggesting a microbiome-based avenue that...
If validated, epithelial CXCL1 could become a tissue biomarker that helps track remission specifically in ulcerative colitis and serve as a functional readout for epithelial-directed therapies tested in patient-derived...
A planned 5-year cohort focused on newly diagnosed Crohn’s patients could identify patterns of bowel damage and predictors of surgery or disability, which may eventually help tailor treatments and monitoring.
Early changes in stool tests (qFIT and fecal calprotectin) might help predict which biologic‑naive ulcerative colitis patients will relapse or need escalation to biologic/JAK therapy. If validated, such markers could...
Early, noninvasive stool tests (fecal calprotectin and FIT) might identify whether vedolizumab or infliximab is likely to work within weeks instead of months. That could let patients and clinicians make treatment...
A new Phase 2 study is testing an investigational injectable drug (called “627”) for moderate to severe ulcerative colitis. People with UC who have not responded to or cannot tolerate current therapies are the intended...
Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...
Early company-reported clinical responses in special-access patients and planned Phase 2 trials could signal a new stem-cell therapy approach advancing for fistulising Crohn’s disease — a complication that can be hard to...
Noninvasive TUS can help detect small-bowel inflammation and stenosis in Crohn's disease with high specificity, potentially reducing the need for immediate invasive testing. However, its sensitivity varies by small-bowel...
This study could clarify which imaging test—MRE or IUS—is more accurate or appropriate for monitoring treatment response in Crohn's disease, potentially standardising follow-up and informing patient and clinician...
The review suggests RDW, an inexpensive and widely available blood test parameter, is higher in IBD and correlates with disease activity—meaning it might help clinicians monitor disease alongside other tests.
This meta-analysis pooled long‑term comparative data suggesting vedolizumab may have advantages over infliximab for treatment persistence, 12‑month remission, and safety in biologic‑naive ulcerative colitis — information...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Colectomy. The original article is from Journal of Gastroenterology and...
Vitamin D deficiency is common in people with IBD and may relate to disease activity, complications, and quality of life; understanding this link could influence monitoring and adjunctive care.
If findings translate to humans, creatine might help protect the gut lining and blood vessels during flare and remission, potentially supporting recovery of gut barrier function in ulcerative colitis.
Biosimilars can expand access to effective biologic treatment for people with IBD by reducing costs, but adoption barriers mean some patients may not benefit. Understanding evidence, practical concerns, and...
People with IBD and their clinicians often rely on MRI for monitoring disease; knowing that MRI techniques can also detect other bowel problems helps explain imaging choices and what radiologists may be looking for when...
The work links a missing bacterial metabolite (HDCA) to macrophage metabolism and reduced intestinal inflammation in experimental models, highlighting a potential microbiome-derived pathway that could be targeted for...
This study identifies plant extracts—especially Commiphora gileadensis—that reduced inflammation and tissue injury in cell assays and an acute rat model of ulcerative colitis, suggesting new leads for future IBD drug...
TRPV channels are proposed as integrative mediators of inflammation, angiogenesis, and oxidative stress in IBD, suggesting new mechanistic targets that could eventually yield novel therapies for Crohn's disease and...
Patients with IBD may see TREMFYA appearing more widely as a treatment option and influencing which drugs companies prioritize. Rising sales and trial signals can speed access but don’t replace clinical guidance about...
The study identifies a natural compound that reduced inflammation and improved multiple aspects of intestinal barrier function in a zebrafish IBD model, suggesting a new candidate for preclinical drug discovery relevant...
The report suggests a probiotic (VSL#3TM) added to vedolizumab may speed or increase early response in ulcerative colitis, which could interest patients and clinicians seeking ways to improve biologic induction outcomes....
The study suggests that combining different fermentable fibers may steer the gut microbiome toward more butyrate-producing bacteria and away from pro-inflammatory lineages—changes that could be relevant to IBD-related...
Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Ulcerative colitis and Research and clinical trials. The original article is from Cochrane Database of Systematic...
Older adults with IBD may face different infection risks when treated with advanced biologic therapies. This study aims to compare hospitalizations for serious infections after starting vedolizumab (ENTYVIO) versus TNF...
People with UC on or starting vedolizumab may be interested because the study tests whether adding an oral CurQD supplement improves remission rates compared with vedolizumab alone. The trial could inform whether this...
The record concerns a planned surgical approach using a patient's own bone marrow–derived stem cells to try to heal fistulating perianal Crohn's disease—an often hard-to-treat complication that substantially affects...
Cure8 found this source from Journal of gastroenterology and hepatology, but the page could not be read reliably yet. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials....
The study links TRAIL expression to macrophage behavior and colitis severity in mice and to higher TRAIL levels in human IBD tissue, suggesting TRAIL-related pathways could influence intestinal inflammation and might be...
Environmental pollutants that are increasing in many East Asian settings — air pollution, heavy metals, pesticides, and microplastics — may contribute to rising IBD rates by affecting the gut microbiome and intestinal...
The study identifies a candidate compound (NCTD) that reduced inflammation and tissue damage in a rat ulcerative colitis model and implicates specific inflammatory, epigenetic, metabolic, and antioxidant pathways —...
The study identifies specific anti-inflammatory compounds in Artemisia scoparia and shows they reduce inflammation in cell and mouse models of ulcerative colitis, suggesting potential new leads for drug or...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of...
People with UC can develop severe neutrophilic skin complications like Sweet’s syndrome that may reflect active bowel inflammation even when recent tests suggested remission.
The paper highlights how the gut microbiome and environment can strongly influence colitis severity in genetically susceptible mice, illustrating a gene–environment–microbiome axis that may help explain heterogeneity in...
Vedolizumab blood levels can vary with disease activity; a model that links intestinal α4β7 expression to drug exposure helps explain why some patients have lower drug levels and may need different dosing. This could...
This study suggests there are distinct molecular subtypes of perianal fistulizing Crohn’s disease, and some subtypes may be more likely to benefit from surgical repair while others have higher inflammatory burden and...
The study identifies a potential new mechanism—blocking ferroptosis via CA9—for reducing intestinal inflammation in a mouse model, which could guide future IBD drug research.
This preclinical study suggests quince gel reduced inflammation, oxidative stress, and tissue injury in a rat model of ulcerative colitis and identifies quercetin as a likely active component. Findings point to possible...
Metformin is a common, inexpensive drug with possible anti-inflammatory effects; this review compiles preclinical and early clinical data suggesting it might influence ulcerative colitis biology. Readers may want to know...
This preclinical study identifies benzoylpaeoniflorin (BPF) as a compound that improved experimental colitis in mice by changing macrophage polarization via the RNF31–DPEP2–NF-κB pathway. It highlights a possible...
This NIH-funded project identifies probiotic metabolic pathways that protect gut barrier integrity in a diet-dependent way, which could explain mixed clinical trial results and point to biomarkers to select patients...
The project targets innate lymphocyte pathways that help control mucosal immunity in the gut and airway — mechanisms that can drive or restrain inflammation in IBD and related diseases. Better understanding may reveal...
Researchers are trying to create modular mucosal immunotherapies that target both microbial and inflammatory drivers of diseases like colitis. If successful, this approach could lead to treatments that address the...
